中药辅助治疗卒中后痉挛的系统评价与Meta分析
该系统评价与Meta分析纳入35项随机对照试验共2457例卒中后痉挛患者,评估中药在常规治疗基础上的附加疗效与安全性。结果显示口服或外用中药对上下肢痉挛量表及日常生活能力有改善趋势,但纳入试验质量存在局限,需更严谨研究验证。
要点
- 口服或外用中药联合常规治疗可能改善卒中后痉挛量表评分。
- 中药附加治疗对FMA和BI多数亚组显示更好结果,但口服中药对上肢FMA例外。
核心结论
- 在注意纳入试验质量问题的前提下,本综述提示中药对卒中后痉挛患者似乎是耐受良好的疗法。
- 中药在减轻痉挛和改善日常生活活动方面的潜在附加效应需要进一步严谨评估。
研究设计与样本
- 系统评价与Meta分析,检索5个英文和4个中文数据库,从各自建库至2018年2月28日。
- 纳入评估中药附加效应的随机对照试验,共35项试验涉及2457例患者。
主要发现
- 上肢AS或MAS:口服中药附加常规治疗SMD -1.79(95% CI:-3.00至-0.57),外用中药SMD -1.06(95% CI:-1.40至-0.72)。
- 下肢AS或MAS:口服中药附加常规治疗SMD -1.01(95% CI:-1.43至-0.59),外用中药SMD -1.16(95% CI:-1.83至-0.49)。
- FMA和BI:除口服中药对上肢FMA亚组外,中药附加常规治疗均检测到更好结果。
临床怎么用
- 对卒中后痉挛患者,可考虑在常规治疗基础上加用口服或外用中药,但需结合纳入试验质量局限审慎决策。
- 使用中药附加治疗时应关注安全性信息,现有报告的不良事件为轻度。
局限性
- 纳入试验存在质量担忧,可能影响结论可靠性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Treatment for post-stroke spasticity (PSS) remains a major challenge in clinical practice. Chinese herbal medicine (CHM) is often administered to assist in routine care (RC) in the treatment of PSS, with increasing numbers of clinical research and preclinical studies suggesting that it has potential benefits. Therefore, we conducted a systematic review and meta-analysis to evaluate the add-on effects and safety of CHM for PSS. Methods: Five English and four Chinese databases were searched from their respective inception to 28 February 2018. We included randomized controlled trials that evaluated the add-on effects of CHM for PSS, based on changes in the scores of the (Modified) Ashworth Scale (AS or MAS), Fugl-Meyer Assessment of Sensorimotor Recovery (FMA), and Barthel Index (BI). Results: Thirty-five trials involving 2,457 patients were included. For upper-limb AS or MAS, the estimated add-on effects of CHM to RC were significantly better when using oral (SMD -1.79, 95% CI: -3.00 to -0.57) or topical CHM (SMD -1.06, 95% CI: -1.40 to -0.72). For lower-limb AS or MAS, significant add-on benefits to RC were also detected (SMD -1.01, 95% CI: -1.43 to -0.59 and SMD -1.16, 95% CI: -1.83 to -0.49) using oral and topical CHM, respectively. For FMA and BI, better results were detected when adding CHM to RC, except for the subgroup of oral CHM for upper-limb FMA. Ten of the 35 included studies reported safety information, with two of them mentioning two mild adverse events. Conclusions: Noting the quality concerns of the included trials, this review suggests that CHM appears to be a well-tolerated therapy for patients with PSS, and the potential add-on effects of CHM in reducing spasticity and improving the daily activities of patients with PSS require further rigorous assessment.
引用
- Cai Y, Zhang CS, Liu S, et al. Add-On Effects of Chinese Herbal Medicine for Post-Stroke Spasticity: A Systematic Review and Meta-Analysis. Front Pharmacol. 2019. PMID: 31316387. doi:10.3389/fphar.2019.00734
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。